Managing menopausal symptoms and depression in tamoxifen users: Implications of drug and medicinal interactions

Maturitas

Volumn 67, Issue 4, 2010, Pages 296-308

  Desmarais, Julie Eve ^a,b   Looper, Karl J ^b,c  

^a Allan Memorial Institute   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Depression; Drug interaction or incompatibility; Hot flashes; Menopause; Tamoxifen; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DESIPRAMINE; DESVENLAFAXINE; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MIRTAZAPINE; NEFAZODONE; OXYBUTYNIN; PAROXETINE; PHYTOESTROGEN; PLACEBO; PRASTERONE; PREGABALIN; SERTRALINE; TAMOXIFEN; TIBOLONE; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; ANOREXIA; APPETITE; APPETITE DISORDER; ARTHRALGIA; BLOATING; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DATA BASE; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SOYBEAN; SPOTTING; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; DEPRESSION; DRUG INTERACTIONS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; TAMOXIFEN;

EID: 78649507259     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.08.005     Document Type: Review

References (85)

1. Mayo Clinic The pharmacogenetics of tamoxifen therapy Mayo Reference Services Communiqué 32 1 2007
2. H. Brauch, T.E. Murdter, M. Eichelbaum, and M. Schwab Pharmacogenomics of tamoxifen therapy Clin Chem 55 10 2009 1770 1782
3. A.H. MacLennan, J.L. Broadbent, S. Lester, and V. Moore Oral estrogen and combined oestrogen/progesterone therapy versus placebo for hot flushes Cochrane Database Syst Rev 4 2004 Oct 18 CD002978
4. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 350 9084 1997 1047 1059
5. V. Beral Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 9382 2003 419 427
6. L. Holmberg, O.E. Iversen, C.M. Rudenstam, M. Hammar, E. Kumpulainen, and J. Jaskiewicz Increased risk of recurrence after hormone replacement therapy in breast cancer survivors J Natl Cancer Inst 100 7 2008 475 482
7. I. Sestak, R. Kealy, R. Edwards, J. Forbes, and J. Cuzick Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms J Clin Oncol 24 24 2006 3991 3996
8. C.R. Osborne, A. Duncan, S. Sedlacek, D. Paul, F. Holmes, and S. Vukelja The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer Breast Cancer Res Treat 116 3 2009 521 527
9. J. Bonneterre, A. Buzdar, J.M. Nabholtz, J.F. Robertson, B. Thurlimann, and M. von Euler Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 9 2001 2247 2258
10. A.S. Coates, A. Keshaviah, B. Thurlimann, H. Mouridsen, L. Mauriac, and J.F. Forbes Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 5 2007 486 492
11. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, and T. Delozier A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 11 2004 1081 1092 (Pubitemid 38298988)
12. J. Bonneterre, B. Thurlimann, J.F. Robertson, M. Krzakowski, L. Mauriac, and P. Koralewski Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study J Clin Oncol 18 22 2000 3748 3757
13. M.S. Hunter, E.A. Grunfeld, S. Mittal, P. Sikka, A.J. Ramirez, and I. Fentiman Menopausal symptoms in women with breast cancer: prevalence and treatment preferences Psychooncology 13 11 2004 769 778
14. C.L. Loprinzi, J.C. Michalak, S.K. Quella, J.R. O'Fallon, A.K. Hatfield, and R.A. Nelimark Megestrol acetate for the prevention of hot flashes N Engl J Med 331 6 1994 347 352
15. J.W. Goodwin, S.J. Green, C.M. Moinpour, J.D. Bearden 3rd, J.K. Giguere, and C.S. Jiang Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626 J Clin Oncol 26 10 2008 1650 1656
16. C.L. Loprinzi, R. Levitt, D. Barton, J.A. Sloan, S.R. Dakhil, and D.A. Nikcevich Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7 J Clin Oncol 24 9 2006 1409 1414
17. D.L. Barton, C. Loprinzi, P.J. Atherton, L. Kottschade, M. Collins, and P. Carpenter Dehydroepiandrosterone for the treatment of hot flashes: a pilot study Support Cancer Ther 3 2 2006 91 97
18. P. Kenemans, N.J. Bundred, J.M. Foidart, E. Kubista, B. von Schoultz, and P. Sismondi Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial Lancet Oncol 10 2 2009 135 146
19. R. Kroiss, I.S. Fentiman, F.A. Helmond, J. Rymer, J.M. Foidart, and N. Bundred The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial BJOG 112 2 2005 228 233
20. H.D. Nelson, K.K. Vesco, E. Haney, R. Fu, A. Nedrow, and J. Miller Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis JAMA 295 17 2006 2057 2071
21. C.L. Loprinzi, J. Sloan, V. Stearns, R. Slack, M. Iyengar, B. Diekmann, G. Kimmick, J. Lovato, P. Gordon, K. Pandya, T. Guttuso Jr., D. Barton, and P. Novotny Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis J Clin Oncol 27 17 2009 2831 2837
22. K.A. Toulis, T. Tzellos, D. Kouvelas, and D.G. Goulis Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Clin Ther 31 2 2009 221 235
23. D.L. Barton, C.L. Loprinzi, P. Novotny, T. Shanafelt, J. Sloan, and D. Wahner-Roedler Pilot evaluation of citalopram for the relief of hot flashes J Support Oncol 1 1 2003 47 51
24. D.L. Barton, B.I. LaVasseur, J.A. Sloan, A.N. Stawis, K.A. Flynn, and M. Dyar Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9 J Clin Oncol 28 20 2010 Jul 3278 3283 Epub May 24
25. C.L. Loprinzi, P.J. Flynn, L.A. Carpenter, P. Atherton, D.L. Barton, T.D. Shanafelt, T.A. Rummans, J.A. Sloan, A.A. Adjei, B.A. Mincey, T.R. Fitch, and M. Collins Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine J Palliat Med 8 5 2005 924 930
26. C.L. Loprinzi, J.A. Sloan, E.A. Perez, S.K. Quella, P.J. Stella, and J.A. Mailliard Phase III evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 20 6 2002 1578 1583
27. V. Stearns, R. Slack, N. Greep, R. Henry-Tilman, M. Osborne, and C. Bunnell Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial J Clin Oncol 23 28 2005 6919 6930
28. V. Stearns, K.L. Beebe, M. Iyengar, and E. Dube Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial JAMA 289 21 2003 2827 2834
29. G.G. Kimmick, J. Lovato, R. McQuellon, E. Robinson, and H.B. Muss Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen Breast J 12 2 2006 114 122
30. C.L. Loprinzi, T.M. Pisansky, R. Fonseca, J.A. Sloan, K.M. Zahasky, and S.K. Quella Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors J Clin Oncol 16 7 1998 2377 2381
31. C.L. Loprinzi, J.W. Kugler, J.A. Sloan, J.A. Mailliard, B.I. LaVasseur, and D.L. Barton Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial Lancet 356 9247 2000 2059 2063
32. N. Biglia, R. Torta, R. Roagna, F. Maggiorotto, F. Cacciari, and R. Ponzone Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors Maturitas 52 1 2005 78 85
33. S. Loibl, K. Schwedler, G. von Minckwitz, R. Strohmeier, K.M. Mehta, and M. Kaufmann Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients - a double-blind, randomized study Ann Oncol 18 4 2007 689 693
34. D.G. Perez, C.L. Loprinzi, D.L. Barton, B.A. Pockaj, J. Sloan, and P.J. Novotny Pilot evaluation of mirtazapine for the treatment of hot flashes J Support Oncol 2 1 2004 50 56 (Pubitemid 39430230)
35. D.L. Barton, C.L. Loprinzi, P. Atherton, J. Raymond, T. Shanafelt, and S. Hines Phase II Evaluation of Desipramine for the Treatment of Hot Flashes Support Cancer Ther 4 4 2007 219 224
36. D.G. Perez, C.L. Loprinzi, J. Sloan, P. Novotny, D. Barton, and L. Carpenter Pilot evaluation of bupropion for the treatment of hot flashes J Palliat Med 9 3 2006 631 637 (Pubitemid 43938839)
37. K.J. Pandya, G.R. Morrow, J.A. Roscoe, H. Zhao, J.T. Hickok, and E. Pajon Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial Lancet 366 9488 2005 818 824
38. L. Loprinzi, D.L. Barton, J.A. Sloan, K.M. Zahasky, D.A. Smith, S. Pruthi, P.J. Novotny, E.A. Perez, and B.J. Christensen Pilot evaluation of gabapentin for treating hot flashes Mayo Clin Proc 77 11 2002 1159 1163 (Pubitemid 35266363)
39. C.L. Loprinzi, J.W. Kugler, D.L. Barton, A.C. Dueck, L.K. Tschetter, and R.A. Nelimark Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5 J Clin Oncol 25 3 2007 308 312
40. N. Biglia, P. Sgandurra, E. Peano, D. Marenco, G. Moggio, and V. Bounous Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E Climacteric 12 4 2009 310 318
41. C.L. Loprinzi, R. Qin, E.P. Balcueva, K.A. Flynn, K.M. Rowland Jr., and D.L. Graham Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1 J Clin Oncol 28 4 2010 Feb 1 641 647 Epub 2009 Nov 9
42. S. Thompson, A. Bardia, A. Tan, D.L. Barton, L. Kottschade, and J.A. Sloan Levetiracetam for the treatment of hot flashes: a phase II study Support Care Cancer 16 1 2008 75 82
43. R.M. Goldberg, C.L. Loprinzi, J.R. O'Fallon, M.H. Veeder, A.W. Miser, and J.A. Mailliard Transdermal clonidine for ameliorating tamoxifen-induced hot flashes J Clin Oncol 12 1 1994 155 158
44. K.J. Pandya, R.F. Raubertas, P.J. Flynn, H.E. Hynes, R.J. Rosenbluth, and J.J. Kirshner Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study Ann Intern Med 132 10 2000 788 793
45. T. Sexton, J. Younus, F. Perera, L. Kligman, and M. Lock Oxybutynin for refractory hot flashes in cancer patients Menopause 14 3 Pt 1 2007 505 509
46. D.L. Barton, C.L. Loprinzi, S.K. Quella, J.A. Sloan, M.H. Veeder, and J.R. Egner Prospective evaluation of vitamin E for hot flashes in breast cancer survivors J Clin Oncol 16 2 1998 495 500
47. G. Hernandez Munoz, and S. Pluchino Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer Maturitas 44 Suppl 1 2003 S59 65
48. B.A. Pockaj, C.L. Loprinzi, J.A. Sloan, P.J. Novotny, D.L. Barton, and A. Hagenmaier Pilot evaluation of black cohosh for the treatment of hot flashes in women Cancer Invest 22 4 2004 515 521
49. B.A. Pockaj, J.G. Gallagher, C.L. Loprinzi, P.J. Stella, D.L. Barton, and J.A. Sloan Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1 J Clin Oncol 24 18 2006 2836 2841
50. J.S. Jacobson, A.B. Troxel, J. Evans, L. Klaus, L. Vahdat, and D. Kinne Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer J Clin Oncol 19 10 2001 2739 2745
51. C.L. Van Patten, I.A. Olivotto, G.K. Chambers, K.A. Gelmon, T.G. Hislop, and E. Templeton Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial J Clin Oncol 20 6 2002 1449 1455
52. S.K. Quella, C.L. Loprinzi, D.L. Barton, J.A. Knost, J.A. Sloan, and B.I. LaVasseur Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial J Clin Oncol 18 5 2000 1068 1074
53. C.A. MacGregor, P.A. Canney, G. Patterson, R. McDonald, and J. Paul A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer Eur J Cancer 41 5 2005 708 714
54. J.R. Fann, A.M. Thomas-Rich, W.J. Katon, D. Cowley, M. Pepping, B.A. McGregor, and J. Gralow Major depression after breast cancer: a review of epidemiology and treatment Gen Hosp Psychiatry 30 2 2008 112 126
55. R. Day, P.A. Ganz, and J.P. Costantino Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study J Natl Cancer Inst 93 21 2001 1615 1623
56. K.C. Lee, G.T. Ray, E.M. Hunkeler, and P.R. Finley Tamoxifen treatment and new-onset depression in breast cancer patients Psychosomatics 48 3 2007 205 210
57. M. Reich Depression and cancer: recent data on clinical issues, research challenges and treatment approaches Curr Opin Oncol 20 4 2008 353 359
58. Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J, 2010 Mar 23. [Epub ahead of print].
59. S. Borges, Z. Desta, L. Li, T.C. Skaar, B.A. Ward, and A. Nguyen Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 1 2006 61 74
60. J. Gjerde, M. Hauglid, H. Breilid, S. Lundgren, J.E. Varhaug, and E.R. Kisanga Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism Ann Oncol 19 1 2008 56 61
61. M.P. Goetz, J.M. Rae, V.J. Suman, S.L. Safgren, M.M. Ames, and D.W. Visscher Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 36 2005 9312 9318
62. W. Schroth, L. Antoniadou, P. Fritz, M. Schwab, T. Muerdter, and U.M. Zanger Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 33 2007 5187 5193
63. K. Kiyotani, T. Mushiroda, M. Sasa, Y. Bando, I. Sumitomo, and N. Hosono Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 5 2008 995 999
64. S. Borges, Z. Desta, Y. Jin, A. Faouzi, J.D. Robarge, and S. Philip Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients J Clin Pharmacol 50 4 2010 Apr 450 458 Epub 2010 Jan 15
65. P. Wegman, S. Elingarami, J. Carstensen, O. Stal, B. Nordenskjold, and S. Wingren Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 1 2007 R7
66. S.A. Nowell, J. Ahn, J.M. Rae, J.O. Scheys, A. Trovato, and C. Sweeney Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 3 2005 249 258
67. P. Wegman, L. Vainikka, O. Stal, B. Nordenskjold, L. Skoog, and L.E. Rutqvist Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 3 2005 R284 R290
68. V. Stearns, M.D. Johnson, J.M. Rae, A. Morocho, A. Novielli, and P. Bhargava Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 23 2003 1758 1764
69. Y. Jin, Z. Desta, V. Stearns, B. Ward, H. Ho, and K.H. Lee CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 1 2005 30 39
70. M.P. Goetz, S.K. Knox, V.J. Suman, J.M. Rae, S.L. Safgren, and M.M. Ames The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 1 2007 113 121
71. C.M. Kelly, D.N. Juurlink, T. Gomes, M. Duong-Hua, K.I. Pritchard, and P.C. Austin Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ 340 2010 Feb 8 c693
72. D. Lehmann, J. Nelsen, V. Ramanath, N. Newman, D. Duggan, and A. Smith Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition J Clin Pharmacol 44 8 2004 861 865
73. J. Chubak, D.S. Buist, D.M. Boudreau, M.A. Rossing, T. Lumley, and N.S. Weiss Breast cancer recurrence risk in relation to antidepressant use after diagnosis Breast Cancer Res Treat 112 1 2008 123 132
74. T.L. Lash, L. Pedersen, D. Cronin-Fenton, T.P. Ahern, C.L. Rosenberg, and K.L. Lunetta Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram Br J Cancer 99 4 2008 616 621
75. T.L. Lash, D. Cronin-Fenton, T.P. Ahern, C.L. Rosenberg, K.L. Lunetta, and R.A. Silliman Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen Acta Oncol 49 3 2010 Apr 305 312
76. V.O. Dezentje, N.J. van Blijderveen, H. Gelderblom, H. Putter, M.P. van Herk-Sukel, and M.K. Casparie Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer J Clin Oncol 28 14 2010 May 10 2423 2429 Epub 2010 Apr 12
77. R.E. Aubert, E.J. Stanek, and J. Yao Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors J Clin Oncol 27 18s 2009
78. J.E. Desmarais, and K.J. Looper Interactions between tamoxifen and antidepressants via cytochrome P450 2D6 J Clin Psychiatry 70 12 2009 1688 1697
79. E.M. Williamson Interactions between herbal and conventional medicines Expert Opin Drug Saf 4 2 2005 355 378
80. N. Guha, M.L. Kwan, C.P. Quesenberry Jr., E.K. Weltzien, A.L. Castillo, and B.J. Caan Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study Breast Cancer Res Treat 118 2 2009 395 405
81. A.H. Wu, M.C. Pike, L.D. Williams, D. Spicer, C.C. Tseng, and M.I. Churchwell Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer J Clin Oncol 25 21 2007 3024 3030
82. X.O. Shu, Y. Zheng, H. Cai, K. Gu, Z. Chen, and W. Zheng Soy food intake and breast cancer survival JAMA 302 22 2009 2437 2443
83. G. Deng, A. Davatgarzadeh, S. Yeung, and B. Cassileth Phytoestrogens: science, evidence, and advice for breast cancer patients J Soc Integr Oncol 8 1 2010 Winter 20 30
84. D.F. Archer Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes Maturitas 66 1 2010 May 1 2 Epub 2010 Mar 7
85. C.L. Loprinzi, B. Diekmann, P.J. Novotny, V. Stearns, and J.A. Sloan Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration Menopause 16 5 2009 883 887